Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...

Japanese scientists conducted a clinical trial using stem cells to treat severe corneal damage. The trial involved four ...

Researchers successfully tested the safety and preliminary efficacy of stem-cell-derived corneal implants, showing promise ...